A novel intravesical targeted drug delivery system for patients with bladder cancer has demonstrated positive data in updated results from a Phase I trial.
The new findings were taken from:
- Cohort 1: patients with recurrent, Bacillus Calmette-Guérin (BCG)-unresponsive high-risk (HR) NMIBC (high-grade Ta/T1; papillary only) who refused or were ineligible for radical cystectomy
- Cohort 3 patients with recurrent, intermediate-risk NMIBC (Ta/T1) low-grade papillary disease left in situ as tumour marker lesions.
At the data cutoff (
- The 12-month recurrence-free survival rate was 90 percent in 21 HR-NMIBC patients (Cohort 1)
- A complete response rate of 90 percent was observed in 31 efficacy evaluable patients (Cohort 3).
The 12-month recurrence-free survival rate was 90 percent in 21 HR-NMIBC patients (Cohort 1)”
TAR-210: a promising alternative treatment option
"Advancement in the treatment landscape of high- or intermediate-risk non-muscle-invasive bladder cancer has remained stagnant for more than 50 years," stated Dr
These results further support the potential of TAR-210 with quarterly administration as a bladder-sparing and BCG-free treatment option”
The findings “further support the potential of TAR-210 with quarterly administration as a bladder-sparing and BCG-free treatment option," commented Dr
These data for the drug delivery system for erdafitinib were featured at the 2024
Moreover, initial study findings were featured at the
The post Intravesical drug delivery system exhibits bladder cancer benefit appeared first on European Pharmaceutical Review.
© Russell Publishing Limited, 2024. All Rights Reserved., source